Endometrial preparation before the transfer of single, vitrified-warmed, euploid blastocysts: does the duration of estradiol treatment influence clinical outcome?
Adult
Blastocyst
Cryopreservation
Drug Administration Schedule
Embryo Implantation
/ drug effects
Endometrium
/ drug effects
Estradiol
/ administration & dosage
Female
Fertility Agents, Female
/ administration & dosage
Fertilization in Vitro
Humans
Infertility
/ diagnosis
Live Birth
Pregnancy
Pregnancy Complications
/ etiology
Pregnancy Rate
Retrospective Studies
Risk Factors
Single Embryo Transfer
/ adverse effects
Time Factors
Treatment Outcome
Vitrification
Endometrial preparation
FET
estrogen
perinatal outcomes
pregnancy
vitrification
Journal
Fertility and sterility
ISSN: 1556-5653
Titre abrégé: Fertil Steril
Pays: United States
ID NLM: 0372772
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
23
08
2018
revised:
17
02
2019
accepted:
18
02
2019
pubmed:
29
4
2019
medline:
23
10
2019
entrez:
29
4
2019
Statut:
ppublish
Résumé
To investigate whether the duration of estrogen administration before euploid embryo transfer affects clinical outcome. Retrospective cohort study. Private, academic fertility center. Patients (n = 1,439) undergoing autologous freeze-only in vitro fertilization with preimplantation genetic testing (PGT) followed by endometrial preparation with estrogen and progesterone in a frozen, euploid blastocyst transfer cycle. None. Primary outcome was live birth, and secondary outcomes included implantation, clinical pregnancy, early pregnancy loss, live birth, infant birthweight, low birth weight, infant gestational age at delivery, and preterm birth. The duration of estrogen administration (mean: 17.5 ± 2.9 days; range: 10-36 days) before frozen embryo transfer did not impact implantation (odds ratio [OR] 0.99; 95% confidence interval [CI], 0.95-1.03), clinical pregnancy (OR 0.98; 95% CI, 0.94-1.01), early pregnancy loss (OR 1.03; 95% CI, 0.95-1.12), or live birth (OR 0.99; 95% CI, 0.95-1.03). The duration of estrogen exposure did not affect infant birthweight (in grams) (β= -10.65 ± 8.91) or the odds of low birth weight (OR 0.87; 95% CI, 0.68-1.13). For every additional day of estrogen administration, we observed a reduction in gestational age at delivery (in weeks) (β= -0.07 ± 0.03), but the odds of preterm delivery were not affected (OR 1.05; 95% CI, 0.95-1.17). Variation in the duration of estradiol supplementation before progesterone initiation does not impact frozen, euploid blastocyst transfer outcome. The duration of estrogen administration was inversely correlated with gestational age at delivery, but this did not translate into an increase in preterm delivery. Further studies are required on the downstream effects of endometrial preparation on the placental-endometrium interface.
Identifiants
pubmed: 31029432
pii: S0015-0282(19)30135-9
doi: 10.1016/j.fertnstert.2019.02.024
pii:
doi:
Substances chimiques
Fertility Agents, Female
0
Estradiol
4TI98Z838E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1177-1185.e3Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.